Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18

Articles

52102 items
12:00 AM, Nov 08, 2000  |  BC Extra | Clinical News

ImClone releases Phase II IMC-C225 results

IMCL announced preliminary results of its open-label, Phase II trial of IMC-C225 with irinotecan in patients with irinotecan-refractory colorectal carcinoma. IMCL said the combination therapy resulted in tumor shrinkage and slowing of disease progression. IMC-C225...
12:00 AM, Nov 08, 2000  |  BC Extra | Clinical News

FDA suspends NeoRx's Phase III STR studies

The FDA suspended accrual and treatment in NERX's trials of its Skeletal Targeted Radiotherapy (STR) radiolabeled bone-targeting small molecule, including a Phase III study to treat multiple myeloma, following the development of thrombotic thrombocytopenic purpura/hemolytic...
12:00 AM, Nov 08, 2000  |  BC Extra | Financial News

MediChem sells shoe

MCLS, a supplier of tools and services for drug discovery, raised $6.7 million through the sale of 960,000 shares at $7 authorized to cover overallotments in its IPO. The sale brings to $51.5 million the...
12:00 AM, Nov 08, 2000  |  BC Extra | Financial News

Corvas raises $15 million from shoe

CVAS raised $15 million through the exercise of the 750,000-share overallotment in its previously completed follow-on, bringing the total raised in the deal to $115 million (see BioCentury, Nov. 6). Underwriters included CIBC World...
12:00 AM, Nov 08, 2000  |  BC Extra | Company News

Modex to acquire BioCare Biotechnologie

Modex (SWX:MDXN) will acquire marketing partner BioCare (Leipzig, Germany) for a maximum of DM1.1 million ($489,000) in treasury shares and up to DM1.2 million in cash dependent on milestones. BioCare markets its ThromboKinin autologous growth...
12:00 AM, Nov 07, 2000  |  BC Extra | Top Story

Dow and Diversa in chiral compound deal

The companies will jointly market their techniques to produce chirally pure compounds for pharmaceutical companies. DVSA will use its high-throughput technology to develop enzymes used as biocatalysts in the production of pure chiral compounds, and...
12:00 AM, Nov 07, 2000  |  BC Extra | Financial News

Pozen sells shoe

POZN raised $11.3 million through the sale of 750,000 shares at $15 authorized to cover overallotments in its October IPO. The sale brings to $86.3 million the total raised in the deal, underwritten by U.S....
12:00 AM, Nov 07, 2000  |  BC Extra | Company News

Drew to acquire CDC Technology for $8 million

Drew Scientific (LSE:DRW), a diagnostics company, plans to acquire CDC Technologies (Oxford, Conn.) for $8 million. CDC produces hematology analyzers....
12:00 AM, Nov 07, 2000  |  BC Extra | Company News

MediChem and Degussa form alliance

Degussa-Huls (Milan, Italy) will allow MCLS to access its fine chemical division's cGMP-certified facilities for development and production of pharmaceutical active ingredients. The alliance also gives Degussa-Huls access to MCLS's technologies for the development and...
12:00 AM, Nov 07, 2000  |  BC Extra | Company News

Oxford GlycoSciences and Incyte amend deal

Oxford GlycoSciences (LSE:OGS) and INCY will continue their proteomics collaboration to develop INCY's LifeExpress database under revised terms. The companies will switch from an exclusive profit sharing arrangement to non-exclusive contract payments. INCY will retain...

Pages